Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial

Table 2 Summary of least squares mean (SEM) change from baseline in secondary efficacy endpoints at week 12 (proof-of-concept component; FAS, LOCF)

	Placebo	Maraviroc 300 mg BID	Pvalue
ACR components
Tender/painful joint count	-3.41 (1.19) [n = 33]	-4.89 (0.84) [n = 77]	0.294
Swollen joint count	-3.43 (0.95) [n = 33]	-3.48 (0.66) [n = 77]	0.966
Patient's assessment of arthritis pain	-6.09 (4.06) [n = 33]	-8.30 (2.85) [n = 77]	0.644
Patient's global assessment of arthritis	-6.78 (4.06) [n = 33]	-8.55 (2.88) [n = 76]	0.712
Physician's global assessment of arthritis	-0.36 (0.15) [n = 32]	-0.49 (0.11) [n = 75]	0.490
HAQ-DI	-0.06 (0.13) [n = 20]	-0.18 (0.08) [n = 55]	0.396
SF-36 version 2 (acute)
Physical component summary	4.81 (1.65) [n = 19]	3.14 (1.04) [n = 53]	0.344
Mental component summary	0.61 (2.25) [n = 19]	1.17 (1.41) [n = 53]	0.818

ACR, American College of Rheumatology; BID, twice daily; FAS, full analysis set; HAQ-DI, health assessment questionnaire-disability index; LOCF, last observation carried forward; SEM, standard error of the mean; SF-36, Short Form-36 Health Survey.